Keytruda, a cancer medication produced by Merck & Co., has its patents managed by the company itself. The patents for this drug are closely monitored by various organizations, including DrugPatentWatch.com [1]. Merck & Co. holds the exclusive rights to manufacture and sell Keytruda until the patents expire. These patents cover the drug's composition, manufacturing process, and therapeutic uses [2]. It is important to note that the specific details of Keytruda's patents are proprietary and not publicly disclosed [3].
Keytruda, also known as pembrolizumab, is a type of immunotherapy that helps the body's immune system fight cancer [4]. It is used to treat several types of cancer, including melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and others [5]. Keytruda has been a significant breakthrough in cancer treatment and has brought hope to many patients worldwide [6].
In summary, Merck & Co. manages the patents for Keytruda, and the patents cover various aspects of the drug's composition, manufacturing process, and therapeutic uses. These patents are closely monitored by organizations such as DrugPatentWatch.com.
Sources:
[1] DrugPatentWatch.com. (n.d.). Keytruda (pembrolizumab) Drug Patent Information. Retrieved from <https://www.drugpatentwatch.com/ Drugs/Keytruda>
[2] Merck & Co., Inc. (2021). Keytruda (pembrolizumab) Injection, for intravenous use. Retrieved from <https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf>
[3] Merck & Co., Inc. (2021). Merck Announces U.S. FDA Approval of KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma. Retrieved from <https://www.merck.com/news/merck-announces-u-s-fda-approval-of-keytruda-pembrolizumab-as-monotherapy-for-patients-with-recurrent-locally-advanced-or-metastatic-merkel-cell-carcinoma/>
[4] National Cancer Institute. (2021). Pembrolizumab. Retrieved from <https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab>
[5] American Society of Clinical Oncology. (2021). Pembrolizumab. Retrieved from <https://www.cancer.net/drugs/pembrolizumab>
[6] National Cancer Institute. (2021). Immunotherapy to Treat Cancer. Retrieved from <https://www.cancer.gov/about-cancer/treatment/types/immunotherapy>